Dry eye: diagnosis and current treatment strategies
One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative...
Gespeichert in:
| Veröffentlicht in: | Current allergy and asthma reports 2004-07, Vol.4 (4), p.314-319 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 4 |
| container_start_page | 314 |
| container_title | Current allergy and asthma reports |
| container_volume | 4 |
| creator | O'Brien, Paul D Collum, Louis M T |
| description | One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer. Tear replacement or preservation using artificial tears and/or punctal occlusion are the mainstay of treatment. Newer forms of therapy were designed to modify the underlying disease process. These include the use of topical cyclosporin A, autologous serum, and sodium hyaluronate drops, which suppress underlying inflammation, provide growth factors, and prevent the onset of squamous metaplasia in ocular surface epithelium. Hormonal therapy might have a role in the future of dry eye therapy. |
| doi_str_mv | 10.1007/s11882-004-0077-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71975122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2409855011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-b0e3baa1f1d83ad9faee3ed1fa04bd999350681de216b352cd4c92d18af550703</originalsourceid><addsrcrecordid>eNpdkE1PwzAMhiMEYmPwA7igigO3gJ00TcMNjU9pEhc4R2njTp3WdiTtYf-eVpuExMGyD49f2Q9j1wj3CKAfImKeCw6QjqU1FydsjkqmPJOoTqdZGK6lEDN2EeMGQIyYOGczVKgVpnrO5HPYJ7Snx8TXbt12sY6Ja31SDiFQ2yd9INc30xT74Hpa1xQv2VnltpGujn3Bvl9fvpbvfPX59rF8WvFSirTnBZAsnMMKfS6dN5UjkuSxcpAW3hgjFWQ5ehKYFVKJ0qelER5zVykFGuSC3R1yd6H7GSj2tqljSduta6kbotVoxi-EGMHbf-CmG0I73mZzbTKVA0xpeIDK0MUYqLK7UDcu7C2CnXTag0476rSTTjsF3xyDh6Ih_7dx9Cd_AVInbzI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879658000</pqid></control><display><type>article</type><title>Dry eye: diagnosis and current treatment strategies</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>O'Brien, Paul D ; Collum, Louis M T</creator><creatorcontrib>O'Brien, Paul D ; Collum, Louis M T</creatorcontrib><description>One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer. Tear replacement or preservation using artificial tears and/or punctal occlusion are the mainstay of treatment. Newer forms of therapy were designed to modify the underlying disease process. These include the use of topical cyclosporin A, autologous serum, and sodium hyaluronate drops, which suppress underlying inflammation, provide growth factors, and prevent the onset of squamous metaplasia in ocular surface epithelium. Hormonal therapy might have a role in the future of dry eye therapy.</description><identifier>ISSN: 1529-7322</identifier><identifier>EISSN: 1534-6315</identifier><identifier>DOI: 10.1007/s11882-004-0077-2</identifier><identifier>PMID: 15175147</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Androgens - biosynthesis ; Androgens - therapeutic use ; Anti-Inflammatory Agents - therapeutic use ; Cyclosporine - therapeutic use ; Dry Eye Syndromes - diagnosis ; Dry Eye Syndromes - physiopathology ; Dry Eye Syndromes - therapy ; Humans ; Hyaluronic Acid - therapeutic use ; Lacrimal Apparatus - physiopathology ; Medical treatment ; Ophthalmic Solutions - therapeutic use ; Tears - metabolism</subject><ispartof>Current allergy and asthma reports, 2004-07, Vol.4 (4), p.314-319</ispartof><rights>Current Science Inc. 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-b0e3baa1f1d83ad9faee3ed1fa04bd999350681de216b352cd4c92d18af550703</citedby><cites>FETCH-LOGICAL-c324t-b0e3baa1f1d83ad9faee3ed1fa04bd999350681de216b352cd4c92d18af550703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15175147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Brien, Paul D</creatorcontrib><creatorcontrib>Collum, Louis M T</creatorcontrib><title>Dry eye: diagnosis and current treatment strategies</title><title>Current allergy and asthma reports</title><addtitle>Curr Allergy Asthma Rep</addtitle><description>One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer. Tear replacement or preservation using artificial tears and/or punctal occlusion are the mainstay of treatment. Newer forms of therapy were designed to modify the underlying disease process. These include the use of topical cyclosporin A, autologous serum, and sodium hyaluronate drops, which suppress underlying inflammation, provide growth factors, and prevent the onset of squamous metaplasia in ocular surface epithelium. Hormonal therapy might have a role in the future of dry eye therapy.</description><subject>Androgens - biosynthesis</subject><subject>Androgens - therapeutic use</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dry Eye Syndromes - diagnosis</subject><subject>Dry Eye Syndromes - physiopathology</subject><subject>Dry Eye Syndromes - therapy</subject><subject>Humans</subject><subject>Hyaluronic Acid - therapeutic use</subject><subject>Lacrimal Apparatus - physiopathology</subject><subject>Medical treatment</subject><subject>Ophthalmic Solutions - therapeutic use</subject><subject>Tears - metabolism</subject><issn>1529-7322</issn><issn>1534-6315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1PwzAMhiMEYmPwA7igigO3gJ00TcMNjU9pEhc4R2njTp3WdiTtYf-eVpuExMGyD49f2Q9j1wj3CKAfImKeCw6QjqU1FydsjkqmPJOoTqdZGK6lEDN2EeMGQIyYOGczVKgVpnrO5HPYJ7Snx8TXbt12sY6Ja31SDiFQ2yd9INc30xT74Hpa1xQv2VnltpGujn3Bvl9fvpbvfPX59rF8WvFSirTnBZAsnMMKfS6dN5UjkuSxcpAW3hgjFWQ5ehKYFVKJ0qelER5zVykFGuSC3R1yd6H7GSj2tqljSduta6kbotVoxi-EGMHbf-CmG0I73mZzbTKVA0xpeIDK0MUYqLK7UDcu7C2CnXTag0476rSTTjsF3xyDh6Ih_7dx9Cd_AVInbzI</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>O'Brien, Paul D</creator><creator>Collum, Louis M T</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Dry eye: diagnosis and current treatment strategies</title><author>O'Brien, Paul D ; Collum, Louis M T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-b0e3baa1f1d83ad9faee3ed1fa04bd999350681de216b352cd4c92d18af550703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Androgens - biosynthesis</topic><topic>Androgens - therapeutic use</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dry Eye Syndromes - diagnosis</topic><topic>Dry Eye Syndromes - physiopathology</topic><topic>Dry Eye Syndromes - therapy</topic><topic>Humans</topic><topic>Hyaluronic Acid - therapeutic use</topic><topic>Lacrimal Apparatus - physiopathology</topic><topic>Medical treatment</topic><topic>Ophthalmic Solutions - therapeutic use</topic><topic>Tears - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Brien, Paul D</creatorcontrib><creatorcontrib>Collum, Louis M T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current allergy and asthma reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Brien, Paul D</au><au>Collum, Louis M T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dry eye: diagnosis and current treatment strategies</atitle><jtitle>Current allergy and asthma reports</jtitle><addtitle>Curr Allergy Asthma Rep</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>4</volume><issue>4</issue><spage>314</spage><epage>319</epage><pages>314-319</pages><issn>1529-7322</issn><eissn>1534-6315</eissn><abstract>One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer. Tear replacement or preservation using artificial tears and/or punctal occlusion are the mainstay of treatment. Newer forms of therapy were designed to modify the underlying disease process. These include the use of topical cyclosporin A, autologous serum, and sodium hyaluronate drops, which suppress underlying inflammation, provide growth factors, and prevent the onset of squamous metaplasia in ocular surface epithelium. Hormonal therapy might have a role in the future of dry eye therapy.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>15175147</pmid><doi>10.1007/s11882-004-0077-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1529-7322 |
| ispartof | Current allergy and asthma reports, 2004-07, Vol.4 (4), p.314-319 |
| issn | 1529-7322 1534-6315 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71975122 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Androgens - biosynthesis Androgens - therapeutic use Anti-Inflammatory Agents - therapeutic use Cyclosporine - therapeutic use Dry Eye Syndromes - diagnosis Dry Eye Syndromes - physiopathology Dry Eye Syndromes - therapy Humans Hyaluronic Acid - therapeutic use Lacrimal Apparatus - physiopathology Medical treatment Ophthalmic Solutions - therapeutic use Tears - metabolism |
| title | Dry eye: diagnosis and current treatment strategies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dry%20eye:%20diagnosis%20and%20current%20treatment%20strategies&rft.jtitle=Current%20allergy%20and%20asthma%20reports&rft.au=O'Brien,%20Paul%20D&rft.date=2004-07-01&rft.volume=4&rft.issue=4&rft.spage=314&rft.epage=319&rft.pages=314-319&rft.issn=1529-7322&rft.eissn=1534-6315&rft_id=info:doi/10.1007/s11882-004-0077-2&rft_dat=%3Cproquest_cross%3E2409855011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879658000&rft_id=info:pmid/15175147&rfr_iscdi=true |